GLP-1 drugs, like Ozempic, Wegovy, and Zepbound, have gained attention for their significant health impacts and anti-obesity effects. However, there continues to be a lot of unknowns surrounding these medications, their long-term impacts, and access.
Featuring: Dr. Lydia Alexander, an obesity medicine specialist, lifestyle specialist, president of the Obesity Medicine Association (OMA), Chief Medical Officer at Enara, and a medical chef.
In today’s episode, we’ll cover
- The significant progress made in GLP-1 research, care delivery, and insurance coverage
- Filling research gaps in GLP-1 care through longitudinal studies examining long-term medication effects and potential adverse reactions
- Tips for providers managing patients on GLP-1 medications and patient-focused approaches to obesity management
And more!
To watch video clips from our podcast, subscribe to our YouTube channel, @Healthcare Strategies
Resources:
- Are compounded “DIY” peptides the answer to the GLP-1 shortage?
- Exploring FDA-approved GLP-1 receptor agonists
- Addressing muscle loss associated with GLP-1 medication use
Informações
- Podcast
- FrequênciaSemanal
- Publicado11 de novembro de 2024 09:00 UTC
- Duração17min
- Temporada6
- Episódio8
- ClassificaçãoLivre